CD146 (MCAM), expressed in endothelial cells, pericytes, and mesenchymal cells, is associated with mesenchymal features and poor prognosis in GBM, and its presence on EVs has been linked to organ targeting and metastatic niche formation [71,72]. Here, MCAM is linked to glioblastoma.